Vaxcyte, Inc. (PCVX)
63.89
+1.97
(+3.18%)
USD |
NASDAQ |
Nov 06, 16:00
63.88
0.00 (0.00%)
After-Hours: 20:00
Vaxcyte Total Long Term Debt (Quarterly) : 215.14M for Sept. 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 215.14M |
| June 30, 2026 | 108.94M |
| March 31, 2026 | 110.21M |
| December 31, 2025 | 111.36M |
| September 30, 2025 | 78.67M |
| June 30, 2025 | 79.54M |
| March 31, 2025 | 81.08M |
| December 31, 2024 | 65.22M |
| September 30, 2024 | 18.32M |
| June 30, 2024 | 18.29M |
| March 31, 2024 | 20.22M |
| December 31, 2023 | 22.11M |
| September 30, 2023 | 7.781M |
| June 30, 2023 | 9.222M |
| March 31, 2023 | 10.64M |
| December 31, 2022 | 12.03M |
| Date | Value |
|---|---|
| September 30, 2022 | 13.36M |
| June 30, 2022 | 14.56M |
| March 31, 2022 | 15.83M |
| December 31, 2021 | 11.51M |
| September 30, 2021 | 0.553M |
| June 30, 2021 | 0.225M |
| March 31, 2021 | 0.295M |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.161M |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Moderna, Inc. | 4.206B |
| Vir Biotechnology, Inc. | 81.46M |
| Anavex Life Sciences Corp. | 0.00 |
| Revolution Medicines, Inc. | 1.202B |
| Foghorn Therapeutics, Inc. | 40.28M |